Medpace Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>MH</div>
MEDP -- USA Stock  

USD 162.43  3.41  2.14%

Medpace Holdings Accounts Payable Turnover is very stable at the moment as compared to the past year. Medpace Holdings reported last year Accounts Payable Turnover of 50.59. As of 14th of February 2021, Accrued Expenses Turnover is likely to grow to 14.12, while Average Equity is likely to drop about 722.7 M. As some conservative investors are getting more into healthcare space, Medpace Holdings could be a your radar. We will check if it is still possible for Medpace Holdings to minimize net losses this year. In this post, I will also go over a few different drivers affecting Medpace Holdings' products and services, and explain how it may impact Medpace Holdings insiders.
Published over a week ago
View all stories for Medpace Holdings | View All Stories
Reasons Medpace Holdings (NASDAQ:MEDP) can excite insiders
Macroaxis provides trade recommendations on Medpace Holdings to complement and cross-verify current analyst consensus on Medpace Holdings. Our advice engine determines the firm's potential to grow exclusively from the perspective of an investor's current risk tolerance and investing horizon.

How important is Medpace Holdings's Liquidity

Medpace Holdings financial leverage refers to using borrowed capital as a funding source to finance Medpace Holdings ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Medpace Holdings financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Medpace Holdings's total debt and its cash.

How Medpace utilizes its cash?

To perform a cash flow analysis of Medpace Holdings, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Medpace Holdings is receiving and how much cash it distributes out in a given period. The Medpace Holdings cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Medpace Holdings Net Cash Flow from Operations is very stable at the moment as compared to the past year. Medpace Holdings reported last year Net Cash Flow from Operations of 258.68 Million

What did Medpace Holdings file with SEC?

The SEC filings are financial statements or other formal documents of Medpace Holdings that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database.
Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Medpace shareholders may or may not be submitted as SEC does not always require it.
16th of February 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
11th of February 2021
Unclassified Corporate Event
View
30th of October 2020
Other Events
View
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Medpace shareholders may or may not be submitted as SEC does not always require it.

Breaking down Medpace Holdings Indicators

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Medpace Holdings has an asset utilization ratio of 91.07 percent. This suggests that the company is making $0.91 for each dollar of assets. An increasing asset utilization means that Medpace Holdings is more efficient with each dollar of assets it utilizes for everyday operations.
 2018 2019 2020 2021 (projected)
Accounts Payable16.74 M22.4 M20.16 M16.35 M
Receivables133.45 M155.66 M140.1 M114.6 M

Medpace may start a relapse in March

The sortino ratio is down to 0.24 as of today. Medpace Holdings has relatively low volatility with skewness of -0.37 and kurtosis of 1.07. However, we advise all investors to independently investigate Medpace Holdings to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.

Our Final Takeaway

Although some other entities under the diagnostics & research industry are still a bit expensive, Medpace Holdings may offer a potential longer-term growth to insiders. The bottom line, as of the 14th of February 2021, we believe Medpace Holdings is currently overvalued. It responds to the market and projects very small chance of distress in the next two years. However, our overall 30 days recommendation on the firm is Strong Buy.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Medpace Holdings. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com